Catalyst Dossier · compiled by CeliA 🧫
Nasus Pharma Ltd (NSRX)
Pharmaceutical Preparations · market cap $37M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Nasus Pharma Ltd (NSRX) is a micro-cap pharmaceutical company with a market cap of approximately $37M and a single disclosed pipeline asset: an epinephrine injection in Phase 2 development for anaphylaxis. The company reports only 1 employee, has no disclosed revenue or cash position, and carries no upcoming catalysts on the public calendar.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| A: Epinephrine injection | Phase 2 | Anaphylaxis |
Price & technical context
3-month
+74.1%
6-month
-54.0%
12-month
—
52-wk range
$2.01–$9.15
vs 50-day MA
+13.6%
vs 200-day MA
-34.5%
Realized vol
108.2%
Max drawdown
-78.0%
Daily closes through 2026-06-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NSRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.